Call for changes in clinical trial reporting of older patients with cancer

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 893-894

  Lichtman, Stuart M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN;

AGED; CANCER MORTALITY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COMORBIDITY; GERIATRIC PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; STOMACH CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; STOMACH NEOPLASMS;

EID: 84858833968     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.0696     Document Type: Letter

References (5)

1. Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968- 3976, 2011
2. Haider SI, Johnell K, Thorslund M, et al: Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 - 2002. Int J Clin Pharmacol Ther 45:643-653, 2007 (Pubitemid 350268038)
3. Repetto L, Venturino A, Vercelli M, et al: Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 82:760- 765, 1998
4. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999 (Pubitemid 30035956)
5. Ocana A, Amir E, Seruga B: Clinical research: Show us the data. J Clin Oncol 29:1099-1100, 2011